**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 57392

**Manuscript Type:** CASE REPORT

**SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma mimicking solid pseudopapillary neoplasm: A case report and review of the literature**

Hua Y *et al*. SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma mimicking SPN

Yinan Hua, Piyush Soni, Douglas Larsen, Riyam Zreik, Bing Leng, Debby Rampisela

**Yinan Hua, Piyush Soni, Douglas Larsen, Riyam Zreik, Bing Leng, Debby Rampisela,** Department of Pathology, Baylor Scott & White Health, Texas A&M University College of Medicine, Temple, TX 76508, United States

**Author contributions:** All authors contributed to the writing and revising of the manuscript.

**Corresponding author: Debby Rampisela, MD, Attending Doctor,** Department of Pathology, Baylor Scott & White Health, Texas A&M University College of Medicine, 2401 S. 31st Street, MS-01-266, Temple, TX 76508, United States. [debby.rampisela@bswhealth.org](mailto:debby.rampisela@bswhealth.org)

**Received:** June 10, 2020

**Revised:** June 29, 2020

**Accepted:** September 5, 2020

**Published online:**

**Abstract**

BACKGROUND

SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma is a very aggressive tumor that is rarely reported in the literature. The tumor has a predominant rhabdoid cell component and different patterns of growth have been reported.

CASE SUMMARY

A 59-year-old woman presented with diffuse abdominal pain, increasing in severity and accompanied by weight loss, nausea, and vomiting. Imaging showed a pancreatic head mass. Fine needle aspiration demonstrated atypical epithelioid cells with a pseudopapillary growth pattern suggestive of solid pseudopapillary neoplasm. The excised neoplasm showed monotonous epithelioid and focally spindle cells with pseudopapillary structures, rhabdoid features, and loss of SMARCB1 protein expression with wild-type *KRAS*, consistent with a SMARCB1/INI1-deficient undifferentiated rhabdoid carcinoma. The patient’s condition deteriorated rapidly following surgery and she expired 3 mo post operation.

CONCLUSION

In this article, we report the first case of SMARCB1/INI1-deficient undifferentiated pancreatic rhabdoid carcinoma mimicking solid pseudopapillary neoplasm.

**Key words:** Pancreatic undifferentiated rhabdoid carcinoma; Solid pseudopapillary neoplasm; SMARCB1/INI1; *KRAS*; Case report

Hua Y, Soni P, Larsen D, Zreik R, Leng B, Rampisela D. SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma mimicking solid pseudopapillary neoplasm: A case report and review of the literature. *World J Gastroenterol* 2020; In press

**Core tip:** The presence of a pseudopapillary architectural pattern in pancreatic tumors sampled via fine needle aspiration commonly leads to solid pseudopapillary neoplasm as the primary diagnostic consideration, particularly in middle-aged women; however, an inconclusive immunohistochemistry profile may suggest an alternative diagnosis. Our case highlights that while SMARCB1/INI1-deficient pancreatic undifferentiated carcinomas may mimic solid pseudopapillary neoplasm, recognition of this aggressive malignancy is important as these rare tumors impart a dismal prognosis.

**INTRODUCTION**

Pancreatic undifferentiated carcinoma is a group of neoplasms comprised of pleomorphic giant cell carcinoma, sarcomatoid carcinoma, rhabdoid carcinoma, and round cell carcinomas. Pancreatic undifferentiated rhabdoid carcinoma, characterized by a predominant rhabdoid cell component, is a very rare tumor with high lethality. Patients often die within weeks or months of diagnosis. The first case of pancreatic rhabdoid carcinoma was reported in 1997[1]. A recent study by Agaimy *et al*[2] reported the phenotypic and molecular heterogeneity of pancreatic undifferentiated rhabdoid carcinoma. Two subtypes of the tumor were described based on the tumor’s *KRAS* status and SMARCB1 expression. The pleomorphic giant cell subtype displays *KRAS* alterations with preservation of SMARCB1 expression; in contrast, the anaplastic monomorphic subtype shows absence of *KRAS* alterations with loss of SMARCB1 expression. To our best knowledge, eight SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinomas have been reported in the literature[2-6]. Our case is the first reported case with a solid and pseudopapillary growth pattern mimicking solid pseudopapillary neoplasm (SPN).

**CASE PRESENTATION**

***Chief complaints***

A 59-year-old woman presented to the clinic with diffuse abdominal pain.

***History of present illness***

The patient complained of diffuse abdominal pain with increased intensity for approximately 4 wk, accompanied by weight loss, nausea, and vomiting.

***History of past illness***

The patient had a past medical history of back pain, gastroesophageal reflux disease, allergic rhinitis and hepatitis A; and a past surgical history of appendectomy, cholecystectomy, Cesarean section, and ovarian cyst removal.

***Physical examination***

The abdomen was soft, nondistended, but tender to palpation in the right upper quadrant with no rebound or guarding. A well-healed scar was noted below the umbilicus midline, intersecting with a Cesarean section scar.

***Laboratory examinations***

The patient had elevated laboratory values of alkaline phosphatase and aspartate aminotransferase.

***Imaging examinations***

The patient underwent a computed topography (CT) scan of abdomen and pelvis, and an abdominal magnetic resonance imaging (MRI) scan. CT scan revealed a hypodense region in the head of the pancreas, and the follow-up MRI revealed a 3.1 cm pancreatic head mass. Endoscopic ultrasound-guided fine needle aspiration (FNA) of the pancreatic mass was performed and a diagnosis of low-grade neoplasm with papillary features most suggestive of a SPN was rendered.

***Pathological findings***

The FNA specimen was hypercellular with a prominent pseudopapillary growth pattern (Figure 1A). Abundant discohesive tumor cells were also present. The tumor cells were small to intermediate-sized, predominantly epithelioid with round to oval nuclei, inconspicuous to prominent nucleoli, and focal nuclear grooves. Some tumor cells exhibited eccentric nuclei, prominent nucleoli and large cytoplasmic vacuoles (Figure 1B). The tumor cells on the cell block section showed eosinophilic cytoplasm with no obvious rhabdoid features. Immunohistochemically, the tumor cells were diffusely positive for vimentin, very focally positive for synaptophysin and pankeratin (AE1/AE3), and negative for CD10, progesterone receptor, alpha 1-antitrypsin, CD56 and chromogranin. No nuclear beta-catenin stain was noted. Although the immunohistochemical profile was not conclusive, a diagnosis of a low grade neoplasm with papillary features most suggestive of SPN was made.

The enucleated pancreatic mass was received in two parts, measuring 3.4 cm × 2.4 cm × 1.1 cm and 2.0 cm × 1.0 cm × 0.4 cm. Histological sections showed a heterogeneous tumor with areas of solid and pseudopapillary growth and focal hemorrhage (Figure 2A). A subpopulation of the neoplastic cells was intermediate-sized, epithelioid and focally spindled with mild to moderate nuclear pleomorphism and indistinct to prominent nucleoli. Nuclear grooves were focally appreciated. However, a second subpopulation (approximately 60% of the neoplastic cells) showed rhabdoid features with eccentrically located nuclei, prominent nucleoli, abundant eosinophilic cytoplasm and eosinophilic cytoplasmic inclusions (Figure 2B). By immunohistochemistry, the neoplastic cells were diffusely positive for vimentin and focally positive for pankeratin (AE1/AE3), OSCAR keratin, CD34, Cyclin D1, synaptophysin and CD56. The tumor cells were negative for DOG1, CD117/KIT, desmin, STAT6, progesterone receptor, neuron-specific enolase, trypsin, chromogranin, CD99, CD10, SOX10, and S100. Beta-catenin immunostaining showed focal loss of membranous expression without nuclear expression. E-cadherin immunostaining showed patchy loss of membranous expression. The proliferation index Ki-67 demonstrated variable expression, ranging from less than 10% (non-rhabdoid cells) to over 50% (rhabdoid cells). PD-L1 highlighted less than 1% tumor cells, which was interpreted as negative for PD-L1 expression. SMARCB1/INI1 immunostaining showed complete loss of nuclear staining in all tumor cells. Next generation sequencing using the Ion AmpliSeqTM Cancer Hotspot Panel v2 confirmed loss of SMARCB1 gene with wild type *KRAS* gene.

**FINAL DIAGNOSIS**

The final diagnosis was SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma.

**TREATMENT**

The patient was treated with pancreatic mass enucleation approximately 4 mo after the initial presentation of abdominal pain.

**OUTCOME AND FOLLOW-UP**

The patient’s post operation course was complicated by small mesenteric artery (SMA) thrombosis, small bowel ischemia, perforated small bowel and intra-abdominal abscess. She underwent a small bowel resection, an open thrombectomy of the SMA and a placement of a drainage for the abdominal abscess. She was readmitted twice to the hospital following episodes of upper gastrointestinal bleeding due to multiple ulcers, which were treated with epinephrine injections and cauteries. Follow up CT of the abdomen and pelvis 1 mo and 2 mo post-pancreatic mass enucleation showed multiple intrahepatic cystic masses that increased in size, suspicious for malignancy. Subsequent core biopsy of the liver mass was consistent with a metastatic pancreatic undifferentiated rhabdoid carcinoma. The patient’s condition deteriorated rapidly and she expired 3 mo after pancreatic mass enucleation.

**DISCUSSION**

SMARCB1/INI1, ubiquitously expressed in the nuclei of all normal cells, is an important player in the SWI/SNF ATP-dependent chromatin-remodeling complex[7]. Cell biology studies have revealed a wide spectrum of signaling cascades regulated by SMARCB1, including p16-RB pathway, canonical WNT pathway, sonic hedgehog pathway, and polycomb pathway[8]. More importantly, aberrant expression of SMARCB1 has been found in a variety of tumors[7,9]. In particular, malignant rhabdoid tumor, epithelioid sarcoma, sinonasal carcinoma, renal medullary carcinoma, and pancreatic undifferentiated rhabdoid carcinoma can exhibit complete loss of SMARCB1 expression. SMARCB1 immunohistochemistry has been well established as a highly sensitive and specific tool for detecting malignant rhabdoid neoplasms[9].

SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma is an aggressive and rare primary malignancy of the pancreas. According to the current World Health Organization classification of pancreatic tumors, undifferentiated pancreatic carcinoma is defined as a malignant epithelial neoplasm in which a substantial component of the neoplasm does not show a definitive line of differentiation[10]. The incidence of undifferentiated pancreatic carcinoma is only about 2% to 7% of all pancreatic cancers. A spectrum of histologic variants, including anaplastic rhabdoid carcinoma, sarcomatoid spindle cell carcinoma, carcinosarcoma with recognizable adenocarcinoma and high-grade spindle cell areas, as well as undifferentiated carcinoma with osteoclast-like giant cells, have been recognized[1-6,11-17]. Agaimy *et al*[2] pointed out that pancreatic undifferentiated rhabdoid carcinoma (undifferentiated carcinoma with rhabdoid features) showed heterogeneous morphology but could be separated into two subtypes: pleomorphic giant cell subtype (positive for *KRAS* alterations and intact SMARCB1 expression) and anaplastic monomorphic cell subtype (loss of SMARCB1 expression and wild type *KRAS* expression). The prognosis of both subtypes of the undifferentiated rhabdoid carcinoma is poor (no reported cases with 5-year survival). In contrast, the undifferentiated carcinoma with osteoclastic giant cells appears to confer a more favorable prognosis with 5-year survival of approximately 50%[18,19].

To our best knowledge, eight SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinomas have been reported in the literature (Table 1). Eight of the nine cases (including our case) had clinical data. The patients consisted of three males and five females, ranging from 35 to 76 years. Tumor sizes ranged from 1.9 cm to 10 cm. Five cases originated in the pancreatic head, two in the tail, and one in the body. Six cases had distant metastases and three were not specified. Six cases had follow up and all of the patients died of disease either post-operatively or within 2 wk to 7 mo following the initial diagnosis (mean: 3.6 mo, median: 3.5 mo). The histologic patterns of the tumors were heterogeneous with pseudopapillary acantholytic gland-like spaces, angiosarcoma-like, proximal-type epithelioid sarcoma-like, solid/diffuse, mucoid/myxoid stromal and solid patterns. Our case had solid and pseudopapillary features mimicking SPN. All nine cases had complete loss of SMARCB1 by immunohistochemistry. Six cases had wild-type *KRAS*, one was positive for *KRAS* mutation, and two cases were not tested. PD-L1 immunostaining were performed on two cases including our case, and both cases were negative for PD-L1 expression. Based on the limited number of the cases, the prognosis of SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma is dismal.

SPN is a rare low-grade malignant pancreatic neoplasm composed of poorly cohesive epithelial cells forming solid and pseudopapillary structures that lack of a specific line of pancreatic epithelial differentiation. The histology shows solid nests of poorly cohesive cells forming a cuff surrounding blood vessels, resulting in a pseudopapillary architecture. The stroma usually shows various degrees of hyalinization or evidence of degeneration such as hemorrhage, foamy macrophages, calcification and cholesterol clefts. The tumor cells usually have a moderate amount of eosinophilic cytoplasm with perinuclear vacuoles, relatively uniform nuclei with finely textured chromatin, inconspicuous nucleoli and longitudinal grooves, and often containing intracytoplasmic hyaline globules. High-grade malignant transformation of SPN with an aggressive clinical course has been reported[20-23]. The morphological features predicting high-grade transformation include diffuse growth pattern, extensive tumor necrosis, significant nuclear atypia, high mitotic rate and presence of an undifferentiated component[20], while typical histologic architecture and cytological features of a SPN are always present. The tumor cells of SPN express vimentin, CD56, alpha 1-antichymotrypsin, alpha 1-antitrypsin, cyclin D1, CD10 and progesterone receptor. The tumor cells may also show focal immunoreactivity for synaptophysin and cytokeratins. The tumor always shows beta-catenin mutation with nuclear and cytoplasmic staining for beta-catenin immunostaining, including areas of high-grade transformation[20,24]. On the other hand, majority of the pancreatic undifferentiated carcinoma shows only diffuse positivity for vimentin and focal for cytokeratin[10] with no nuclear immunoreactivity for beta-catenin. Although our case showed solid/pseudopapillary architecture and cytological features mimicking SPN, especially on the FNA specimen, the immunostaining pattern and molecular findings on the enucleation specimen did not support the diagnosis of SPN. The findings were consistent with a SMARCB1/INI1-deficient undifferentiated rhabdoid carcinoma.

**CONCLUSION**

In conclusion, here we report a rare case of SMARCB1/INI1-deficient pancreatic undifferentiated rhabdoid carcinoma with cytological and architectural features mimicking SPN. Recognition of this entity is very important due to the poor prognosis of undifferentiated rhabdoid carcinoma compared to SPN, which has much better prognosis. More studies are warranted for the better understanding of pancreatic undifferentiated rhabdoid carcinoma, particularly the SMARCB1/INI1-deficient subtype.

**ACKNOWLEDGEMENTS**

We thank Dr. Rondell Graham at Mayo Clinic for his expertise.

**REFERENCES**

1 **Nishihara K**, Katsumoto F, Kurokawa Y, Toyoshima S, Takeda S, Abe R. Anaplastic carcinoma showing rhabdoid features combined with mucinous cystadenocarcinoma of the pancreas. *Arch Pathol Lab Med* 1997; **121**: 1104-1107 [PMID: 9341593]

2 **Agaimy A**, Haller F, Frohnauer J, Schaefer IM, Ströbel P, Hartmann A, Stoehr R, Klöppel G. Pancreatic undifferentiated rhabdoid carcinoma: KRAS alterations and SMARCB1 expression status define two subtypes. *Mod Pathol* 2015; **28**: 248-260 [PMID: 25103069 DOI: 10.1038/modpathol.2014.100]

3 **Sano M**, Homma T, Hayashi E, Noda H, Amano Y, Tsujimura R, Yamada T, Quattrochi B, Nemoto N. Clinicopathological characteristics of anaplastic carcinoma of the pancreas with rhabdoid features. *Virchows Arch* 2014; **465**: 531-538 [PMID: 25031015 DOI: 10.1007/s00428-014-1631-5]

4 **Ohike N,** Suzuki R, Isobe T, Norose T, Shiokawa A, Kunimura T, Kohashi K, Oda Y. A case of pancreatic undifferentiated carcinoma mimicking proximal-type epithelioid sarcoma. *J Pancreas* 2016; **17**: 75-80

5 **Tahara S**, Takeyari M, Morii E. Usefulness of cytological analysis in the diagnosis of pancreatic undifferentiated rhabdoid carcinoma. *Pathol Int* 2018; **68**: 56-58 [PMID: 29235210 DOI: 10.1111/pin.12616]

6 **Lehrke HD**, Graham RP, McWilliams RR, Lam-Himlin DM, Smyrk TC, Jenkins S, Dong H, Zhang L. Undifferentiated Pancreatic Carcinomas Display Enrichment for Frequency and Extent of PD-L1 Expression by Tumor Cells. *Am J Clin Pathol* 2017; **148**: 441-449 [PMID: 29069274 DOI: 10.1093/ajcp/aqx092]

7 **Hollmann TJ**, Hornick JL. INI1-deficient tumors: diagnostic features and molecular genetics. *Am J Surg Pathol* 2011; **35**: e47-e63 [PMID: 21934399 DOI: 10.1097/PAS.0b013e31822b325b]

8 **Kohashi K**, Oda Y. Oncogenic roles of SMARCB1/INI1 and its deficient tumors. *Cancer Sci* 2017; **108**: 547-552 [PMID: 28109176 DOI: 10.1111/cas.13173]

9 **Agaimy A**. The expanding family of SMARCB1(INI1)-deficient neoplasia: implications of phenotypic, biological, and molecular heterogeneity. *Adv Anat Pathol* 2014; **21**: 394-410 [PMID: 25299309 DOI: 10.1097/PAP.0000000000000038]

10 **Hruban RH**, Adsay NV, Esposito I. Pancreatic ductal adenocarcinoma. World Health Organization Classification of Tumor. Digestive System Tumours. 5th Edition. Lyon: IARC Press, 2019

11 **Kuroda N**, Sawada T, Miyazaki E, Hayashi Y, Toi M, Naruse K, Fukui T, Nakayama H, Hiroi M, Taguchi H, Enzan H. Anaplastic carcinoma of the pancreas with rhabdoid features. *Pathol Int* 2000; **50**: 57-62 [PMID: 10692179 DOI: 10.1046/j.1440-1827.2000.00996.x]

12 **Chadha MK**, LeVea C, Javle M, Kuvshinoff B, Vijaykumar R, Iyer R. Anaplastic pancreatic carcinoma. A case report and review of literature. *JOP* 2004; **5**: 512-515 [PMID: 15536293]

13 **Cho YM**, Choi J, Lee OJ, Lee HI, Han DJ, Ro JY. SMARCB1/INI1 missense mutation in mucinous carcinoma with rhabdoid features. *Pathol Int* 2006; **56**: 702-706 [PMID: 17040295 DOI: 10.1111/j.1440-1827.2006.02033.x]

14 **Jamali M**, Serra S, Chetty R. Adenosquamous carcinoma of the pancreas with clear cell and rhabdoid components. A case report. *JOP* 2007; **8**: 330-334 [PMID: 17495363]

15 **Kuroda N**, Iwamura S, Fujishima N, Ohara M, Hirouchi T, Mizuno K, Hayashi Y, Lee GH. Anaplastic carcinoma of the pancreas with rhabdoid features and hyaline globule-like structures. *Med Mol Morphol* 2007; **40**: 168-171 [PMID: 17874050 DOI: 10.1007/s00795-006-0349-0]

16 **Al-Nafussi A**, O'Donnell M. Poorly differentiated adenocarcinoma with extensive rhabdoid differentiation: clinicopathological features of two cases arising in the gastrointestinal tract. *Pathol Int* 1999; **49**: 160-163 [PMID: 10355971 DOI: 10.1046/j.1440-1827.1999.00839.x]

17 **Layfield LJ**, Bentz J. Giant-cell containing neoplasms of the pancreas: an aspiration cytology study. *Diagn Cytopathol* 2008; **36**: 238-244 [PMID: 18335561 DOI: 10.1002/dc.20785]

18 **Paniccia A**, Hosokawa PW, Schulick RD, Henderson W, Kaplan J, Gajdos C. A matched-cohort analysis of 192 pancreatic anaplastic carcinomas and 960 pancreatic adenocarcinomas: A 13-year North American experience using the National Cancer Data Base (NCDB). *Surgery* 2016; **160**: 281-292 [PMID: 27085687 DOI: 10.1016/j.surg.2016.02.025]

19 **Muraki T**, Reid MD, Basturk O, Jang KT, Bedolla G, Bagci P, Mittal P, Memis B, Katabi N, Bandyopadhyay S, Sarmiento JM, Krasinskas A, Klimstra DS, Adsay V. Undifferentiated Carcinoma With Osteoclastic Giant Cells of the Pancreas: Clinicopathologic Analysis of 38 Cases Highlights a More Protracted Clinical Course Than Currently Appreciated. *Am J Surg Pathol* 2016; **40**: 1203-1216 [PMID: 27508975 DOI: 10.1097/PAS.0000000000000689]

20 **Tang LH**, Aydin H, Brennan MF, Klimstra DS. Clinically aggressive solid pseudopapillary tumors of the pancreas: a report of two cases with components of undifferentiated carcinoma and a comparative clinicopathologic analysis of 34 conventional cases. *Am J Surg Pathol* 2005; **29**: 512-519 [PMID: 15767807 DOI: 10.1097/01.pas.0000155159.28530.88]

21 **Matsuo H**, Ikoma H, Morimura R, Arita T, Kosuga T, Konishi H, Murayama Y, Komatsu S, Shiozaki A, Kuriu Y, Nakanishi M, Ichikawa D, Fujiwara H, Okamoto K, Otsuji E. [A Case Report of an Undifferentiated Pancreatic Carcinoma Diagnosed as a Solid Pseudopapillary Neoplasm before Surgery]. *Gan To Kagaku Ryoho* 2016; **43**: 2350-2352 [PMID: 28133318]

22 **Kim JH**, Lee JM. Clinicopathologic Review of 31 Cases of Solid Pseudopapillary Pancreatic Tumors: Can We Use the Scoring System of Microscopic Features for Suggesting Clinically Malignant Potential? *Am Surg* 2016; **82**: 308-313 [PMID: 27097622 DOI: 10.1177/000313481608200414]

23 **Tomioka K**, Ohike N, Aoki T, Enami Y, Fujimori A, Koizumi T, Kusano T, Nogaki K, Tashiro Y, Wada Y, Hakozaki T, Shibata H, Hirai T, Yamazaki T, Fujimasa K, Norose T, Isobe T, Murakami M. Solid Pseudopapillary Neoplasm of the Pancreas with High-Grade Malignant Transformation Involving p16-RB Pathway Alterations. *Case Rep Surg* 2020; **2020**: 5980382 [PMID: 32158585 DOI: 10.1155/2020/5980382]

24 **Tanaka Y**, Kato K, Notohara K, Hojo H, Ijiri R, Miyake T, Nagahara N, Sasaki F, Kitagawa N, Nakatani Y, Kobayashi Y. Frequent beta-catenin mutation and cytoplasmic/nuclear accumulation in pancreatic solid-pseudopapillary neoplasm. *Cancer Res* 2001; **61**: 8401-8404 [PMID: 11731417]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained.

**Conflict-of-interest statement:** No conflict of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** June 9, 2020

**First decision:** June 18, 2020

**Article in press:**

**Specialty type:** Pathology

**Country/Territory of origin:** United States

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): C

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Carloni R **S-Editor:** Wang JL **L-Editor: P-Editor:**

**Figure Legends**



**Figure 1 Fine needle aspiration smears of the pancreatic tumor.** A: Pseudopapillary growth pattern and discohesive tumor cells (Papanicolaou stain, 40 ×); B: Tumor cells with mild to moderate cytologic atypia and large intracytoplasmic vacuoles (Papanicolaou stain, 400 ×).



**Figure 2 Histomorphology of enucleated pancreatic tumor.** A: Pseudopapillary growth pattern (Hematoxylin and eosin stain, 40 ×); B: Tumor cells with rhabdoid features (Hematoxylin and eosin stain, 400 ×); C, D: Immunohistochemistry stains of vimentin (C) and SMARCB1/INI1 (D) (100 ×).

**Table 1 Summary of SMARCB1 deficient pancreatic undifferentiated rhabdoid carcinoma cases in the literature along with our case**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Age/gender** | **Size/pancreatic location** | **Histology** | **Treatment** | **Metastasis** | **Outcome** | ***KRAS* mutation** | **SMARCB1 (IHC)** |
| Agaimy *et al*[2] | 76/M | 5 cm/head | Rhabdoid | Surgery | NS | DOD in 1 mo | Wild type | Complete loss |
| Agaimy *et al*[2] | 44/F | 6 cm/head | Rhabdoid, angiosarcoma-like | Surgery | NS | NS | Positive (pGly12Asp) | Complete loss |
| Agaimy *et al*[2] | 72/M | 4 cm/head | Rhabdoid, pseudopapillary acantholytic gland-like spaces | Surgery | Liver, lymph nodes | DOD post-operatively | Wild type | Complete loss |
| Agaimy *et al*[2] | 61/M | 5 cm/tail | Rhabdoid, prominent neutrophils and focal glandular formation | Surgery | Intra-abdominal, stomach | NS | Wild type | Complete loss |
| Sano *et al*[3] | 68/F | 10 cm/body, tail | Rhabdoid | Palliative | Liver, kidneys, lungs, right adrenal gland, omentum, peritoneum | DOD in 2 wk | NS | Complete loss |
| Ohike *et al*[4] | 35/F | 6 cm/head | Rhabdoid, solid/diffuse | Chemo | Liver | DOD in 7 mo | Wild type | Complete loss |
| Tahara *et al*[5] | 67/F | 1.9 cm/body | Rhabdoid, solid/diffuse | Chemo | Liver, lung, bone, tongue, right thigh | DOD in half year | Wild type | Complete loss |
| Lehrke *et al*[6] | NS | NS | Rhabdoid | NS | NS | NS | NS | Complete loss |
| Our case | 59/F | 3.1 cm/head | Rhabdoid, solid pseudopapillary-like | Surgery | Liver | DOD in 7 mo | Wild type | Complete loss |

*KRAS*: KRAS proto-oncogene GTPase; Chemo: chemotherapy; DOD: Died of disease; NS: Not specified; IHC: Immunohistochemistry.